RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18 VANCOUVER, Washington, Jan. 04, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“ CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer, will host an investment community webcast on Wednesday, January 6, 2021.
Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities:
1) BLA/MAA submissions to Health Canada, MHRA, EMA, and US FDA not done by THTX
2) HIV prevention trial/monotherapy trial not done properly foe NASH Or Oncology
3) Potential revenue from HIV and manufacturing forecast not done properly for HIV, NASH OR Oncology
4) HIV Cure - amfAR not applicable
5) EUA submission timelines to same four agencies for COVID-19, if CD12 Trial results are supportive of an EUA not done for their trials
6) Long-hauler clinical trial and potential data readout timelines not done properly
7) NASH trial and potential interim analysis timeline not done properly
8) Cancer trial Breakthrough Therapy designation potential timelines not done properly
9) GvHD trial status not applicable
10) Stroke/MS new trials in 2021 not applicable
11) NASDAQ uplisting status not applicable
Management will also provide approximately 30-45 minutes to address questions submitted online by analysts and investors. dream on